Treatment of Cryofibrinogenemia Secondary to Autoimmune Disease, Infection, or Lymphoproliferative Disorder
When cryofibrinogenemia (CF) arises in the setting of an identifiable underlying condition, management centres on that condition first. Recognising the secondary nature of CF — and the category of disease driving it — shapes the treatment approach fundamentally.
Clinical Scenario
This protocol applies to patients with cryofibrinogenemia in whom a secondary cause has been identified: an autoimmune disease, an active infection, a solid tumour, or a lymphoproliferative disorder — such as B- or T-cell lymphoma, chronic lymphocytic leukaemia, Waldenström's macroglobulinaemia, or multiple myeloma.
Treatment Approach
Effective management of the underlying disease is the primary therapeutic goal. In patients where an autoimmune condition is the secondary cause, pharmacological therapy — including corticosteroid-based treatment, with or without additional immunosuppressive agents — forms a central part of the approach.
The full structured regimen, sequencing, and clinical decision pathway are available via the protocol below.
References
DOI: 10.1093/rheumatology/kew379
- In at least 30–50% of patients CF is a secondary condition that can be associated with variable auto-immune diseases, infections, solid tumours and lymphoproliferative disorders, such as B or T lymphomas, chronic lymphocytic leukaemia, Waldenstrom's macroglobulinaemia or multiple myeloma.
- In patients with secondary CF, effective management of the underlying disease is usually sufficient to achieve improvement, while approaches to treatment for essential CF in reported patients were variable and ranged from avoidance of cold exposure to aggressive immunosuppression and plasmapheresis.
- Corticosteroids with or without immunosuppressive medications are a mainstay of therapy for secondary CF associated with autoimmune diseases, though they are frequently given to patients with essential CF as well (up to 75% of patients).
View source ↗